Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706987 | 0.98 | USP2 (0.76) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL18484219 | 0.84 | KMT2A (0.86) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL3812763 | 0.84 | KMT2A (0.86) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL5198775 | 0.84 | USP2 (0.80) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL5564371 | 0.84 | KMT2A (0.86) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL7645597 | 0.84 | KMT2A (0.86) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL15945283 | 0.84 | KMT2A (0.86) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL12793726 | 0.82 | ALDH1A1 (0.72) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL436674 | 0.82 | PKM (0.89) | USP2GAAHTTLMNAALDH1A1 | |
| SCHEMBL16442322 | 0.81 | MAPT (0.69) | USP2HTTALDH1A1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108727250-A | Piperidines AMPK agonists and its medical usage | 中国药科大学 | 2018-11-02 | — | — | CN | disclosed |
| EP-2258356-B1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2017-09-27 | — | — | EP | disclosed |
| US-8722742-B2 | Chemical compounds having antiviral activity against Dengue virus and other Flaviviruses | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2014-05-13 | — | — | US | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20110065686-A1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065686-A1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | MAVS, EIF2AK2, ZC3HAV1 | USP2 2696/4885GAA 1687/4885HTT 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.